fate therapeutics buyout

According to analysts' consensus price target of $24.69, Fate Therapeutics has a forecasted upside of 304.1% from its current price of $6.11. See our analysis on Fate Therapeutics Stock Chances of Rise for more details. FT819. Several other research firms have also recently issued reports on FATE. Fate Therapeutics' stock is owned by a variety of institutional and retail investors. Kessler Investment Group LLC bought a new stake in shares of Fate Therapeutics during the 3rd quarter valued at about $82,000. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. BMO Capital Markets cut shares of Fate Therapeutics from an outperform rating to a market perform rating and lowered their target price for the stock from $20.00 to $7.00 in a research note on Friday, January 6th. In other Fate Therapeutics news, Director John Mendlein bought 88,048 shares of Fate Therapeutics stock in a transaction that occurred on Wednesday, January 11th. Question 3: What about the average return after a rise if you wait for a while? According to analysts' consensus price target of $24.69, Fate Therapeutics has a forecasted upside of 305.4% from its current price of $6.09. The company's average rating score is 2.18, and is based on 6 buy ratings, 14 hold ratings, and 2 sell ratings. In announcing the J&J deal, Fate also warned of coronavirus-related "delays or disruptions in patient enrollment and site initiation" that will affect the timing of its clinical trials. FT819 is a first-of-kind, allogeneic, off-the-shelf CAR T-cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line precisely engineered to insert a novel 1XX anti-CD19 chimeric antigen receptor (CAR) under the regulation of the T-cell receptor alpha constant (TRAC) locus for optimized control of anti-tumor activity and to completely delete T-cell receptor (TCR . The shares were sold at an average price of $5.24, for a total value of $38,414.44. Moderna leans into oncology with CytomX deal worth up to $1.2B Fate ends potential $3B Janssen partnership. The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. Is UnitedHealth Stock A Better Pick Over This Healthcare Facility Company? Shares have lost about 21% in that time frame, underperforming the S&P 500. Press Releases. Also, Director John Mendlein purchased 88,048 shares of the businesss stock in a transaction on Wednesday, January 11th. Today it has 9 INDs, more than 250. It is a leading allogeneic (off-the-shelf) NK cell therapy developer which had just 1 IND, 87 employees, and $78mn in cash in 2018. UNLOCK PREMIUM DATA WITH DATABOOST Horizon Therapeutics becomes target of acquisition by pharma giants. Notably, though, the stock is likely to beat S&P500 returns by 4% over the next month (twenty-one trading days). All rights reserved. Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. In comparison, the S&P 500 has an average return of 3.1% over the next 21 trading days under Case 1, and an average return of just 0.5% for Case 2 as detailed in our dashboard that details the average return for the S&P 500 after a fall or rise. Our dashboard, What Factors Drove 1771% Change in Fate Therapeutics Stock between 2017 end and now?, has the underlying numbers. View the best growth stocks for 2023 here. Separately, Fate Therapeutics Chief Scientific Officer - Daniel Shoemaker - will be leaving the company in June this year, and this development has likely hurt the stock. The revenues are expected to see a sharp jump of over 90% to $20.4 million in 2020, due to collaboration agreements with Janssen and Ono. Glassdoor has salaries, wages, tips, bonuses, and hourly pay based upon employee reports and estimates. We believe the stock has rallied meaningfully and it is likely to see downside after the recent uptick. Dive Brief: Johnson & Johnson will pay Fate Therapeutics $100 million to co-develop a group of allogeneic, or "off-the-shelf" cell therapies for cancer. Our dashboard, What Factors Drove 1771% Change in Fate Therapeutics Stock between 2017 end and now?, has the underlying numbers. The stock price of Fate Therapeutics has seen a solid 16% rise over the last five trading days, while its up 13% over the last ten trading days, and we believe the rally may continue in the near term. About Biotech Acquisition Company. : FATE), a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has reached its near-term potential. View which stocks are hot on social media with MarketBeat's trending stocks report. Interestingly, though, if a stock has gained over the last few days, you would do better to avoid short-term bets for most stocks - although FATE stock appears to be an exception to this general observation. The stock was purchased at an average cost of $5.67 per share, for a total transaction of $499,232.16. American Consumer News, LLC dba MarketBeat 2010-2023. How do I buy shares of Fate Therapeutics? With the shares down 60% following Fate's announced pipeline prioritization and Janssen termination, the "damage has largely been done and there is an opportunity for value-based, longer-term investors to step in," Nochomovitz tells investors in a research note. If response rates for its treatments fall, as is usually the case in cancer trials, this stock . Fate Therapeutics has a 52 week low of $4.02 and a 52 week high of $43.12. Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. Shares climbed about 20%, to around $25 apiece, in pre-market trading Friday. Subjects who previously took part in a Fate Therapeutics study and received genetically changed NK cells will take part in this long-term follow-up study. A month has gone by since the last earnings report for Fate Therapeutics (FATE). Fate Therapeutics delivered mixed results for its lymphoma treatments, which caused Fate stock to crumble on Friday.. X. The company's quarterly revenue was up 159.9% on a year-over-year basis. The company is currently working on multiple programs, including FT500, FT516, FT-ONO2, and FATE-NK100 for the treatment of advanced solid tumors. contact@marketbeat.com By Alex Keown. Therefore we cannot guarantee that our site fully works in Internet Explorer. The company has a market cap of $583.99 million, a price-to-earnings ratio of -1.97 and a beta of 1.46. Tesla Investors Arent Impressed With Elon Musk. . Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. Fate Therapeutics is registered under the ticker NASDAQ:FATE . February 28, 2023 - 10:35 am. publish chart | save to portfolio | create alert | compare perf. In their partnership, for instance, Fate and J&J aim to create certain types of immune cells natural killer, or NK cells, and T cells that can hunt down tumors. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares. Fate Therapeutics has received a consensus rating of Hold. The collaboration strengthens our financial and operating position through a focused effort of developing cell-based cancer immunotherapies utilizing Janssens proprietary antigen-binding domains while enabling us to continue to exploit our deep pipeline of wholly-owned product candidates and further develop our off-the-shelf, iPSC-derived cell-based immunotherapies, Wolchko said in a statement. Inventors: Bahram Valamehr, Peter Flynn, Ramzey Abujarour, Megan Robinson Methods and compositions for inducing hematopoietic cell differentiation Patent number: 11162076 Abstract: The invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. Fate Therapeutics (NASDAQ:FATE - Get Rating) had its price target upped by equities research analysts at Citigroup from $9.00 to $10.00 in a report issued on Thursday, The Fly reports. A high percentage of insider ownership can be a sign of company health. Vertex Pharmaceuticals has signed a definitive agreement to acquire all outstanding shares of gene editing therapies developer Exonics Therapeutics for an upfront payment of $245m. Market Volatility To Continue Its The Economy (Stupid)! The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its . The P/E ratio of Fate Therapeutics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. However, looking at the P/S for Fate is not helpful given the company doesnt have any marketable product yet, and it is more of a story of exciting products in the pipeline. Fate is working toward a class of treatment that is based on NK cells. Guggenheim cut shares of Fate Therapeutics from a buy rating to a neutral rating in a research note on Tuesday, January 3rd. The Class A ordinary shares and warrants of BAC trade on the Nasdaq Capital Market under the symbols "BIOT" and "BIOTW," respectively. Twitter Is Just One Reason Why, Gamma Mama! At Tuesday's closing price,. Creates Leading Immunotherapy and Cell Therapy Company. Now that FATE stock has seen a rise of 9% in five trading days, can it continue its upward trajectory, or is a decline imminent? Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD). Per deal terms, J&J will buy $50 million Fate shares at $31 apiece, a roughly 47% premium to Fate's $21.07 closing price on Thursday. Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. Fates iPSC platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses, according to the company. It has seen positive findings from early trials for FT500, preventing disease progression for 11 out of 15 patients, something that has kept the stock price buzzing of late. But now that the stock has fallen 20% in just five days, will the FATE stock resume its downward trajectory over the coming weeks, or is a rise in the stock imminent? 17.34% of the stock of Fate Therapeutics is held by insiders. However, any positive outcome on the trials related to the companys solid tumor treatment candidates will likely result in stock price growth. WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2023, both dates inclusive (the "Class Period"). While the usual process is to create a different batch for each patient from their own stem cells, Fate is intending for mass production of such treatment. Shares of FATE stock can be purchased through any online brokerage account. But now that the stock has fallen 20% in just five days, will the FATE stock resume its downward trajectory over the coming weeks, or is a rise in the stock imminent? The biopharmaceutical company earned $44.36 million during the quarter, compared to analyst estimates of $18.41 million. Fate Therapeutics, Inc. (NASDAQ: FATE) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Welcome to the Fate Therapeutics Fourth Quarter 2022 Financial Results Conference Call.. In related news, CFO Edward J. Dulac III sold 7,331 shares of the companys stock in a transaction dated Tuesday, January 10th. In the last 90 days, insiders have sold 75,708 shares of company stock valued at $396,710. Subscribe to BioPharma Dive for top news, trends & analysis, The free newsletter covering the top industry headlines, By Christopher Newman and Jonathan Gardner , A preclinical trial by the U.S. National Institutes of Health validates the efficacy of Uric A, EUCOPE adds nine new innovative members to its network, From EUCOPE - European Confederation of Pharmaceutical Entrepreneurs, Ymmunobio Welcomes Dr. Kanda and Dr. Khairnar to Advisory Board, Vial Announces the Addition of Dr. Rajat N Agrawal to their Ophthalmology CRO Scientific Advis, By signing up to receive our newsletter, you agree to our, disrupting study enrollment and treatment, Bayer backs cell therapy startup with $215M in funding, Bayer Buys Out BlueRock, Betting at Least $240M More on Cell Therapy Work, 5 questions facing the pharma industry in 2023, FDA clears Intellia to start US tests of in vivo gene editing drug, Novartis takes step toward expanding supply of in-demand cancer drug, Bristol Myers, J&J plan tests of new blood thinner in nearly 50,000 patients, Exelixis reports trial failure for cancer drug combination, How to Implement a Healthy Content Moderation Strategy, How To Build Affordability Programs With Real-time Data, FDA has new power to hold drugmakers accountable. In other news, CFO Edward J. Dulac III sold 7,331 shares of the businesss stock in a transaction that occurred on Tuesday, January 10th. Fate is one of a group of companies advancing an "off-the-shelf" cell therapy approach, which utilizes cells taken from healthy donors. However, looking at the P/S for Fate is not helpful given the company doesnt have any marketable product yet, and it is more of a story of exciting products in the pipeline. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Scott Wolchko has an approval rating of 100% among the company's employees. Subjects will join this study once they complete the parent interventional study. These companies have yet to prove off-the-shelf approaches can match, or surpass, what has been seen with CAR-T without triggering serious or potentially deadly immune reactions. Out of 352 instances in the last eight years that Fate Therapeutics stock saw a five-day rise of 9% or more, 178 of them resulted in FATE stock rising over the subsequent one month period (twenty-one trading days). Last updated: Feb 26, 2023 Powered by IT Spend by Aberdeen This year, Fate Therapeutics is projected to spend $682.2K on IT, according to Aberdeen. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Fate Therapeutics has raised a total of $1.2B in funding over 16 rounds. The 9% rise can primarily be attributed to the announcement of positive interim data from a phase one study for patients with relapsed or refractory B-cell lymphoma. Fates revenue did grow a solid 160% from $4.1 million in 2017 to $10.7 million in 2019. Get the free daily newsletter read by industry experts. Identify stocks that meet your criteria using seven unique stock screeners. Answer: If you buy and hold Fate Therapeutics stock, the expectation is over time the near term fluctuations will cancel out, and the long-term positive trend will favor you - at least if the company is otherwise strong. Finally, Great West Life Assurance Co. Can bought a new stake in shares of Fate Therapeutics during the 3rd quarter valued at about $91,000. The early stage company is also eligible to receive up to $1.8 billion in development and. Shares of the San Diego . Do Wall Street analysts like Fate Therapeutics more than its competitors? A change of 9.3% or more over five trading days (one week) is a 18% likelihood event, which has occurred 352 times out of 1945 in the last 8 years, Of these 352 instances, the stock has seen a positive movement over the next five trading days on 174 occasions, A change of 7% or more over ten trading days is a 31% likelihood event, which has occurred 597 times out of 1945 in the last 8 years, Of these 597 instances, the stock has seen a positive movement over the next ten trading days on 266 occasions, A change of 3.6% or more over twenty-one trading days is a 43% likelihood event, which has occurred 831 times out of 1944 in the last 8 years, Of these 831 instances, the stock has seen a positive movement over the next twenty-one trading days on 464 occasions, A change of 16% or more over 5 trading days is a 9% likelihood event, which has occurred 114 times out of 1256 in the last 5 years, A change of 13% or more over 10 trading days is a 20% likelihood event, which has occurred 252 times out of 1240 in the last 5 years. He said the collaboration combines Janssens deep domain expertise in oncology, along with their proprietary technologies for targeting and binding certain tumors with Fates iPSC product platform to develop novel off-the-shelf CAR NK and T-cell cancer immunotherapies. (844) 978-6257. Shares of Fate Therapeutics were up more than 21% in premarket trading after the company announced a multi-billion dollar deal with Janssen Biotech to develop cell therapies for the treatment of cancer. Major drug pricing legislation passed Congress in 2022, putting pharmaceutical companies on the defensive and creating a new precedent for the industry. With the Hughes Optioneering Strategy, youll soon learn that the safest option for new accounts is options themselves! View analysts price targets for FATE or view top-rated stocks among Wall Street analysts. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. The securities described above are being offered by Fate Therapeutics pursuant to an automatic shelf registration statement on Form S-3 (File No. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. What is Fate Therapeutics' stock price today? CI Investments Inc. now owns 3,082 shares of the biopharmaceutical companys stock valued at $31,000 after purchasing an additional 2,482 shares in the last quarter. Top institutional shareholders include ARK Investment Management LLC (4.34%), Millennium Management LLC (2.95%), Price T Rowe Associates Inc. MD (2.74%), Renaissance Technologies LLC (1.86%), Morgan Stanley (1.79%) and Geode Capital Management LLC (1.61%). Fate turns cells from donors into induced pluripotent stem cells, which in turn can be re-engineered into a variety of different cells. This suggests a possible upside of 304.1% from the stock's current price. I, Fate Therapeutics, Inc. Forecasted to Post Q1 2023 Earnings of ($0.75) Per Share (NASDAQ:FATE), Q1 2023 EPS Estimates for Fate Therapeutics, Inc. (NASDAQ:FATE) Reduced by Analyst, Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2022 Earnings Call Transcript, Fate Therapeutics Full Year 2022 Earnings: Beats Expectations. Topics covered: startup launches, funding, IPOs and much more. Kessler Investment Group LLC bought a new stake in shares of Fate Therapeutics during the 3rd quarter valued at about $82,000. Tesla Investors Arent Impressed With Elon Musk. Segall Bryant & Hamill LLC's holdings in Fate Therapeutics [] The fund owned 153,051 shares of the biopharmaceutical company's stock after purchasing an additional 3,038 shares during the period. But pharma has made notable investments in the work, which could lead to treatments that are quicker and less costly to produce than their autologous counterparts. Using the recent trend (20% fall in a week) and seven years of historical stock data, the Trefis AI engine finds that the stock will likely move 15.1% over the next one month (twenty-one trading days), outperforming the broader indices. NDAQ The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at christina@sternir.com. Gilead to Acquire Forty Seven for $4.9 Billion - Gilead Gains Forty Seven's Investigational Immuno-Oncology Therapy in Multiple Clinical Studies for Diseases Including Myelodysplastic Syndrome, Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma - According to the Trefis Machine Learning Engine, which identifies trends in a companys stock price using historical stock data, returns for FATE stock average around 6% in the next one-month (twenty-one trading days) period after experiencing a 5% fall in a week (five trading days). The stock price of Fate Therapeutics (NASDAQ: FATE), a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a large 20%. The biotech shared an interim peek of data. The 16% rise for FATE stock compares with 4% gains seen in the broader S&P 500 index. Reserve Your Spot With These Hotels The Analysts Support, Cruise Line Stocks Still Have Some Choppy Waters to Navigate, Four Vegan Food Stocks Performing Beyond the Norm, MarketBeat.com's FREE daily email newsletter, Kroger Shares Gap Up on Better-Than-Expected Earnings. By creating a free account, you agree to our, In Britain, warm hubs emerge to beat soaring energy costs, In Chicago, adapting electric buses to winters challenges, Global race to boost electric vehicle range in cold weather, Ukraine ally Kallas fights for reelection in Estonia vote, Paid express lanes grow more popular in once-reluctant South, Pot vote has Oklahoma hungry to rake in green from Texas, Home Depot Stock Earnings Slide, Long Term Value Still There, AbbVie Stock Still a Solid Buy Despite Challenges, President, Chief Executive Officer & Director, Chief Financial Officer & Accounting Officer, Senior Vice President-Technical Operations. Opinions expressed by Forbes Contributors are their own. What is Fate Therapeutics' stock price forecast for 2023? HighTower Advisors LLC now owns 18,361 shares of the biopharmaceutical companys stock valued at $714,000 after purchasing an additional 1,016 shares during the last quarter. Overall, according to data and Trefis machine learning engines calculations, patience absolutely pays for most stocks! Please log in to your account or sign up in order to add this asset to your watchlist. While FATE stock may be overvalued, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. Topics covered: Gene replacement therapy, gene editing, engineered cell therapy, manufacturing, pricing, reimbursement and much more. The firm is home to a robust securities litigation practice and represents investors as well as whistleblowers, workers . According to data from MarketBeat, Fate Therapeutics currently has a consensus rating of Hold and an average price target of $24.69. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA. She looks for companies that are changing the . After a stellar 5x rise since the March 23 levels of last year, at the current price of around $114 per share we believe Fate Therapeutics stock (NASDAQ: FATE), a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has reached its near-term potential. While the usual process is to create a different batch for each patient from their own stem cells, Fate is intending for mass production of such treatment. [Updated: 3/30/2021] Can FATE Stock Rebound? Topics covered: Drug commercialization, pharma salesforces, generic and biosimilar competition, drug advertising and much more. Fate Therapeutics Salaries How much do Fate Therapeutics employees make? Fate is working toward a class of treatment that is based on NK cells. PNC Financial Services Group Inc. now owns 6,737 shares of the biopharmaceutical companys stock worth $260,000 after buying an additional 986 shares during the last quarter. Raymond James & Associates now owns 29,436 shares of the biopharmaceutical companys stock worth $1,141,000 after purchasing an additional 8,790 shares during the period. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Investigator-assessed ORR was 11.4% in patients with NPCB, 16.9% with PCB, and 25.0% in CPI-nave. The Axsome Therapeutics stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The J&J partnership does give Fate some breathing room. Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE.". While we believe that FATE stock is richly valued, the market potential is huge, especially in multi-billion dollar - oncology treatments. Former Qualcomm CEO Steven Mollenkopf, who retired in June 2021, pulled in total compensation of $69 million last year, which ranked highest among CEOs of the region's 100 publicly traded companies. Their FATE share price forecasts range from $7.00 to $90.00. Following the acquisition, the director now owns 246,139 shares in the company, valued at $1,395,608.13. Five Days: FATE 9.3%, vs. S&P500 0.7%; Outperformed market, (18% likelihood event; 49% probability of rise over next 5 days), Ten Days: FATE 7%, vs. S&P500 0.9%; Outperformed market, (31% likelihood event; 45% probability of rise over next 10 days), Twenty-One Days: FATE 3.6%, vs. S&P500 0.01%; Outperformed market, (43% likelihood event; 56% probability of rise over next 21 days). This historical pattern reflects 178 out of 352, or about 49% chance of gain in FATE stock over the coming month. Israel had more companies listed in 2012 on the NASDAQ stock exchange than any country outside the United States, save China. Fate Therapeutics will receive a $50 million upfront payment and a $50 million equity investment. New York, NY-based Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of the central nervous system, disorders for which there are limited. Receive FATE Stock News and Ratings via Email. Given that the company does not have any marketable products currently, it generates revenues primarily from collaboration with other pharmaceutical companies. baseball font with tail generator. As analyst firm Jefferies noted in March, Precision,AllogeneTherapeutics and CRISPRTherapeutics, which each use different off-the-shelf approaches, could all produce notable human data this year. Compare Top Brokerages Here. Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Fate Therapeutics, Inc. has a 52-week low of $4.02 and a 52-week high of $43.12. For more information, call Reed Kathrein at 844-916-0895 or email FATE@hbsslaw.com. Topics covered: Pharma, biotech, FDA, gene therapy, clinical trials, drug pricing and much more. And the recent stock price growth means that some of the positives are already priced in at the current price of $114. Several other hedge funds have also made changes to their positions in FATE. Fate Therapeutics, Inc. (NASDAQ:FATE) issued its quarterly earnings results on Tuesday, February, 28th. Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality Worldwide Bemarituzumab is a Strong Strategic Fit With Amgen's Innovative Oncology Portfolio Amgen to Host Investor Call at 10:30 a.m. EST Following the sale, the chief executive officer now owns 385,639 shares of the companys stock, valued at approximately $2,020,748.36. Es wurde ein Verlust je Aktie von 0 . The disclosure for this sale can be found here. Fate Therapeutics has a 12 month low of $4.02 and a 12 month high of $43.12. C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121: Dulac Edward J Iii: officer: Chief Financial Officer: FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121: Yuan Xu: director: C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080: Robert S .

City Of Shively Ky Occupational Tax, My Favorite Cardigan Knitting Pattern, Articles F